Table 1.
CenterWatch list of new indications related to nephrology, 2002–2012
| Drug | Year Approved | Manufacturer | Indication |
|---|---|---|---|
| Mesnex | 2002 | Bristol-Myers Squibb | Oral tablet to inhibit the hemorrhagic cystitis induced by Ifex |
| Eligard | 2002 | Atrix Laboratories | For the palliative treatment of advanced prostate cancer |
| UroXatral | 2002 | Sanori-aventis | For the treatment of the signs and symptoms of benign prostatic hyperplasia |
| Oxytrol | 2003 | Watson Pharmaceuticals | For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency |
| Fabrazyme | 2003 | Genzyme | For the treatment of Fabry disease in adult patients |
| Vesicare | 2004 | Yamanouchi, GlaxoSmithKline | For the treatment of overactive bladder with symptoms of urge urinary incontinence |
| Sensipar | 2004 | Amgen | For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients |
| Sanctura | 2004 | Indevus Pharmaceuticals | For the treatment of overactive bladder with symptoms of urge urinary incontinence |
| Fosrenol | 2004 | Shire Pharmaceuticals | For the treatment of hyperphosphatemia related to kidney dysfunction |
| Vaprisol | 2005 | Astellas | For the treatment of euvolemic hyponatremia |
| Torisel | 2007 | Wyeth | For the treatment of renal cell carcinoma |
| Renvela | 2007 | Genzyme | For the control of serum phosphorus in patients with CKD on dialysis |
| Mircera | 2007 | Roche | For the treatment of anemia associated with chronic renal failure |
| Doribax | 2007 | Johnson & Johnson | For the treatment of intra-abdominal infections and urinary tract infections |
| Toviaz | 2008 | Pfizer | For the treatment of overactive bladder |
| Degarelix | 2008 | Ferring Pharmaceuticals | For the treatment of prostate cancer |
| Votrient | 2009 | GlaxoSmithKline | For the treatment of renal cell carcinoma |
| Gelnique | 2009 | Watson Pharmaceuticals | For the treatment of overactive bladder |
| Feraheme | 2009 | AMAG | For the treatment of iron deficiency anemia associated with CKD |
| Avastin | 2009 | Genentech | For the treatment of renal cell carcinoma |
| Afinitor | 2009 | Novartis | For the treatment of renal cell carcinoma |
| Zortress | 2010 | Novartis | For the prevention of organ rejection after kidney transplant |
| Xifaxan | 2010 | Salix | For the treatment of hepatic encephalopathy |
| Provenge | 2010 | Dendreon | For the treatment of hormone refractory prostate cancer |
| Jevtana | 2010 | Sanori-aventis | For the treatment of prostate cancer |
| Jalyn | 2010 | GlaxoSmithKline | For the treatment of benign prostatic hyperplasia |
| Carbaglu | 2010 | Recordati | For the treatment of hyperammonemia |
| Soliris | 2011 | Alexion | For the treatment of atypical hemolytic uremic syndrome |
| Nulojix | 2011 | Bristol-Myers Squibb | For the prevention of organ rejection after kidney transplant |
| Anturol | 2011 | Antares Pharma | For the treatment of overactive bladder |
| Voraxaze | 2012 | BTG International | For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function |
| Stivarga | 2012 | Bayer HealthCare Pharmaceuticals | For the treatment of previously treated patients with metastatic colorectal cancer |
| Stendra | 2012 | Vivus | For the treatment of erectile dysfunction |
| Omontys | 2012 | Affymax | For the treatment of anemia caused by CKD |
| Myrbetriq | 2012 | Astellas Pharma US, Inc. | For the treatment of overactive bladder |
| Inlyta | 2012 | Pfizer | For the treatment of advanced renal cell carcinoma |
| Afinitor | 2012 | Novartis | For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex |